CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase IIa Trial of sEphB4-HSA in Combination With Anti PD-1 Antibody (Pembrolizumab, MK3475) in Patients With Non-small Cell Lung and Head/Neck Cancer

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03049618
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:29:01.753385+00:00
Published At: 2025-10-22T00:00:00+00:00
Record Updated At: 2025-10-22
Results Posted At: 2025-10-22
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["ALK Gene Mutation", "BRAF Gene Mutation", "EGFR Gene Mutation", "Head and Neck Squamous Cell Carcinoma", "Metastatic Head and Neck Carcinoma", "Recurrent Head and Neck Carcinoma", "Recurrent Non-Small Cell Lung Carcinoma", "ROS1 Gene Mutation", "Stage III Non-Small Cell Lung Cancer", "Stage IIIA Non-Small Cell Lung Cancer", "Stage IIIB Non-Small Cell Lung Cancer", "Stage IV Non-Small Cell Lung Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-10-22"
protocolSection.identificationModule.nctId: "NCT03049618"
protocolSection.identificationModule.officialTitle: "A Phase IIa Trial of sEphB4-HSA in Combination With Anti PD-1 Antibody (Pembrolizumab, MK3475) in Patients With Non-small Cell Lung and Head/Neck Cancer"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2025-10-22"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.